Cleveland Clinic | Strategic Alliance Partners

July 06, 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

June 29, 2017

Brian Rini, MD, discusses additional adjuvant trials that have perplexed the field, what potential immunotherapy could have in this setting, and other obstacles to tackle in the renal cell carcinoma landscape.

June 23, 2017

Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses the impact of active surveillance on the field of prostate cancer.

June 22, 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the May 2017 FDA approval of pembrolizumab (Keytruda) in patients with urothelial carcinoma.

June 13, 2017

Nima Sharifi, MD, honored by Clinical Research Forum for research showing that testosterone-related genetic mutation leads to deadlier outcomes in prostate cancer.

June 06, 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the results of a study of robot-assisted partial nephrectomy for selected renal mass using an off-clamp approach compared to an on-clamp approach for patients with renal cell carcinoma (RCC).

June 02, 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the significance of a study investigating urinary, bowel, and sexual function at 2 years following the management of localized prostate cancer.

May 16, 2017

An epigenetic strategy under study at Cleveland Clinic combines THU, a cytidine deaminase inhibitor, with decitabine and nivolumab (Opdivo) in patients with non-small cell lung cancer. The results of early studies demonstrate that THU may help prime the immune system.

May 16, 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the recent guidelines for the management of patients with kidney cancer.

May 16, 2017

Gennedy Bratslavsky, MD, deputy director of Upstate Cancer Center, director of the Robotic Program for all Upstate Campuses, and director of the VHL Clinical Cancer Center, discusses the evaluation and management of kidney cancer.

May 16, 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic discusses urinary, bowel, and sexual function following the management of localized prostate cancer.

April 13, 2017

Shlomo Koyfman, MD, discusses the findings of a recent study of patients with HPV-positive oropharyngeal cancer treated with cisplatin-based chemoradiotherapy or cetuximab-based bioradiotherapy.

April 12, 2017

The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.

March 23, 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses informing patients of reirradiation as a treatment for head and neck cancer.

March 16, 2017

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reirradiation for patients with head and neck cancer.

January 20, 2017

Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses a head cooling system that can be used to limit hair loss attributed to chemotherapy treatment for patients with breast cancer.

January 19, 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses recent advancements in reirradiation treatment for patients with head and neck cancer.

January 17, 2017

Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.

January 09, 2017

Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in postmenopausal women with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer. The study looks at the impact of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) in aromatase inhibitor (AI) therapy.

December 15, 2016

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses risk categories that stratified patients in a study evaluating intensity-modulated radiation therapy and stereotactic body radiation therapy to determine outcomes in the reirradiation setting for recurrent head and neck cancer.